Reviewer's report

Title: Medication Utilization Patterns among Type 2 Diabetes Patients Initiating Exenatide BID or Insulin Glargine: A Retrospective Database Study

Version: 2 Date: 22 January 2013

Reviewer: Devada Singh-Franco

Reviewer's report:

Authors encouraged to further explore adverse events associated with exenatide. Tolerability might take several months to accomplish, hence is a possible explanation for longer treatment with exenatide without modification.

Without surrogate markers (HbA1c, fasting glucose), it is unclear how this study describes "real world" use of the agents or that the results are clinically significant.

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

No conflicts to report.